EpCAM (epithelial cell adhesion molecule) was discovered four decades ago as a tumor
antigen on colorectal carcinomas. Owing to its frequent and high expression on carcinomas …

TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but
subsequently shown to be increased in many solid cancers, with lower expression in certain …

Trop-2 is a novel target for ADC therapy because of its high expression by many solid
cancers. The rational development of IMMU-132 represents a paradigm shift as an ADC that …

Expression of the transmembrane glycoprotein EpCam (epithelial cellular adhesion
molecule) occurs in normal epithelium of different organs and was described in carcinomas …

Injection of tumor cells in mice more than 30years ago resulted in the discovery of an
epithelial antigen, later defined as a cell adhesion molecule (EpCAM). Although EpCAM has …

The epithelial glycoprotein 40 (EGP40, also known as GA733-2, ESA, KSA, and the 17-1A
antigen), encoded by the GA-733-2 gene, is expressed on the baso-lateral cell surface in …

The glycoprotein recognized by the monoclonal antibody (mAb) 17–1A is present on most
carcinomas, which makes it an attractive target for immunotherapy. Indeed, adjuvant …

The epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein that is highly
expressed on most carcinomas and therefore of potential use as a diagnostic and prognostic …

Simple Summary Metastatic progression represents a major clinical challenge and remains
the leading cause of death in cancer patients. Identification of suitable therapeutic targets …

With the goal of identifying genes with a differential pattern of expression between ovarian
serous papillary carcinomas (OSPCs) and normal ovarian (NOVA) epithelium and using this …